Single Ascending Doses Study of Anti- Interleukin-7 Receptor α Monoclonal Antibody (GSK2618960) in Healthy Volunteers
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
GSK2618960 is a humanized Immunoglobulin G 1 ( IgG1) monoclonal antibody (mAb) that binds to
the alpha component (CD127) of the heterodimeric Interleukin-7 receptor (IL-7R). It is being
developed for the treatment of autoimmune indications. This study is intended to further
explore the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and
immunogenicity of single ascending doses GSK2618960 in healthy volunteers beyond those
already evaluated in I7R116702 (First Time In Human study). The study is anticipated to enrol
18 subjects in total, with 9 subjects in each of the two cohorts.